ATS
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Personal Folders
Right arrow Download to citation manager
Right arrow Permission Requests
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Naunheim, K. S.
Right arrow Articles by Baue, A. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Naunheim, K. S.
Right arrow Articles by Baue, A. E.

Ann Thorac Surg 1995;59:1085-1090
© 1995 The Society of Thoracic Surgeons

Multimodality Therapy for Adenocarcinoma of the Esophagus

Keith S. Naunheim, MD, Paul J. Petruska, MD, Tapan S. Roy, MD, Jean M. Schlueter, BA, Han Kim, MD, Arthur E. Baue, MD

Division of Cardiothoracic Surgery, St. Louis University Health Sciences Center, St. Louis, Missouri

Few reports exist detailing results of multimodality treatment for adenocarcinoma of the esophagus. We have treated 28 such patients using a preoperative regimen consisting of two courses of cisplatin and 5-fluorouracil with radiation (either 3,000 or 3,600 cGy). There were 25 men and 3 women (mean age, 62.9 years; range, 35 to 86 years), and 16 patients were known to have Barrett's esophagus. Dysphagia was present for a mean of 2.7 months, and the average weight loss was 6.5 kg. Tumors ranged from 2 to 10 cm in length (mean, 5.2 ± 1.8 cm) with American Joint Committee on Cancer clinical stage I in 2 patients, stage II in 19 patients, and stage III in 7. Dysphagia improved in 23 patients (82%), and in 8 (29%) no tumor was detected during radiologic and endoscopic staging after neoadjuvant therapy. Four patients refused operation. Esophagectomy via standard Ivor Lewis approach was accomplished in 20 of 24 patients (87%) undergoing operation. There were no operative deaths, and mean hospital stay was 15.5 ± 11.6 days. Four patients (17%) were complete responders with no tumor in the resected specimen. Actuarial survival in the 28 patients at 1, 2, and 3 years is 71%, 28%, and 20% respectively. Of the 20 esophagectomy patients, 6 are alive with no evidence of disease at 10, 50, 54, 70, 77, and 84 months. Three of these were complete responders. Only 1 of the 8 patients not undergoing resection is alive at 16 months with no evidence of disease after further radiotherapy and chemotherapy. These data suggest that preoperative combined modality therapy for adenocarcinoma of the esophagus is safe and effective treatment. It results in excellent symptomatic improvement, a complete response rate of 17%, and a significant chance for long-term survival.




This article has been cited by other articles:


Home page
 Ann. Thorac. Surg.Home page
J. L. Port, P. C. Lee, R. J. Korst, Y. Liss, D. Meherally, P. Christos, M. Mazumdar, and N. K. Altorki
Positron Emission Tomographic Scanning Predicts Survival After Induction Chemotherapy for Esophageal Carcinoma
Ann. Thorac. Surg., August 1, 2007; 84(2): 393 - 400.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
J. G. Izzo, A. M. Correa, T.-T. Wu, U. Malhotra, C. K.S. Chao, R. Luthra, J. Ensor, A. Dekovich, Z. Liao, W. N. Hittelman, et al.
Pretherapy nuclear factor-{kappa}B status, chemoradiation resistance, and metastatic progression in esophageal carcinoma.
Mol. Cancer Ther., November 1, 2006; 5(11): 2844 - 2850.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Thorac. Surg.Home page
R. J. Korst, A. L. Kansler, J. L. Port, P. C. Lee, Y. Kerem, and N. K. Altorki
Downstaging of T or N Predicts Long-Term Survival After Preoperative Chemotherapy and Radical Resection for Esophageal Carcinoma
Ann. Thorac. Surg., August 1, 2006; 82(2): 480 - 485.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Thorac. Surg.Home page
B. Agarwal, S. G. Swisher, J. Ajani, K. Kelly, R. R. Komaki, E. Abu-Hamda, A. M. Correa, and J. A. Roth
Differential Response to Preoperative Chemoradiation and Surgery in Esophageal Adenocarcinomas Based on Presence of Barrett's Esophagus and Symptomatic Gastroesophageal Reflux
Ann. Thorac. Surg., May 1, 2005; 79(5): 1716 - 1723.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Thorac. Surg.Home page
J. S. Donington, D. L. Miller, M. S. Allen, C. Deschamps, F. C. Nichols III, and P. C. Pairolero
Preoperative chemoradiation therapy does not improve early survival after esophagectomy for patients with clinical stage III adenocarcinoma of the esophagus
Ann. Thorac. Surg., April 1, 2004; 77(4): 1193 - 1199.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Pathol.Home page
B Dunne, J V Reynolds, E Mulligan, A Kelly, and M Griffin
A pathological study of tumour regression in oesophageal adenocarcinoma treated with preoperative chemoradiotherapy
J. Clin. Pathol., November 1, 2001; 54(11): 841 - 845.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
M. M. DeCamp Jr, S. J. Swanson, and M. T. Jaklitsch
Esophagectomy After Induction Chemoradiation*
Chest, December 1, 1999; 116 (2009): 466S - 469S.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Thorac. Surg.Home page
S. J. Hoff, J. L. Sawyers, C. D. Blanke, H. Choy, and J. R. Stewart
Prognosis of Adenocarcinoma Arising in Barrett's Esophagus
Ann. Thorac. Surg., January 1, 1998; 65(1): 176 - 181.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
J.R. Siewert, H.J. Stein, and U. Fink
Multimodality Therapy for Esophageal Cancer
Oncologist, August 1, 1996; 1(4): 210 - 218.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
ANN THORAC SURG ASIAN CARDIOVASC THORAC ANN EUR J CARDIOTHORAC SURG
J THORAC CARDIOVASC SURG ICVTS ALL CTSNet JOURNALS
Copyright © 1995 by The Society of Thoracic Surgeons.